Eli Lilly Acquires Centessa Pharmaceuticals in $6.3B Deal for Narcolepsy Drug Pipeline

Eli Lilly is making a major strategic move into sleep disorders, announcing a $6.3 billion cash acquisition of Centessa Pharmaceuticals. The deal, which values Centessa at a 38% premium over its previous closing price, is centered on securing an experimental drug pipeline designed to combat conditions like narcolepsy. The agreement includes a significant earnout structure, with potential additional payments of up to $1.5 billion if Centessa's drugs achieve U.S. regulatory approval, pushing the total possible value to $47 per share.

Centessa, a biotech firm with dual headquarters in Boston and the U.K., was publicly launched in 2021 with a broad portfolio. It has since sharpened its focus exclusively on disorders of wakefulness, a high-need therapeutic area with limited treatment options. This acquisition represents a substantial premium for Centessa's concentrated pipeline and signals Eli Lilly's aggressive push to expand its neuroscience and rare disease footprint beyond its current blockbuster weight-loss and diabetes franchises.

The transaction immediately pressures other mid-cap biotechs in the neurology and sleep medicine space, as large pharma continues to seek premium assets to fill pipeline gaps. For Eli Lilly, the deal carries both high reward and inherent risk, tying a multi-billion dollar investment to the clinical and regulatory success of still-experimental compounds. The outcome will significantly impact the competitive landscape for next-generation narcolepsy treatments.